

Intellectual Property Prospector

IP Assets Owned by Firms in Transition

March 26, 2007
Volume 2, Number 13
Prospector Profiles in this Issue

| Company Name | Reference Number | Category Profile |
|---|-------------------------|-------------------|
| Advanced Cell Technology, Inc. | 07.0378 | Audit Concerns |
| Advanced Viral Research Corporation | 07.0379 | Audit Concerns |
| Allos Therapeutics, Inc. | 07.0380 | Loss/Deficit |
| Altair Nanotechnologies, Inc. | 07.0381 | Loss/Deficit |
| American Leisure Holdings, Inc. | 07.0382 | Audit Concerns |
| Aquatic Cellulose International Corporation | 07.0383 | Audit Concerns |
| Bally Total Fitness Holding Corp. | 07.0384 | Miscellaneous |
| Bionovo, Inc. | 07.0385 | Loss/Deficit |
| BTX Holdings, Inc. | 07.0386 | Audit Concerns |
| Claimsnet.com, Inc. | 07.0387 | Audit Concerns |
| DNAPrint Genomics, Inc. | 07.0388 | Audit Concerns |
| eLEC Communications Corporation | 07.0389 | Audit Concerns |
| eMerge Interactive, Inc. | 07.0390 | Section 363 Sales |
| Encysive Pharmaceuticals, Inc. | 07.0391 | Audit Concerns |
| Flexpoint Sensor Systems, Inc. | 07.0392 | Audit Concerns |
| Hancock Fabrics, Inc. | 07.0393 | Bankruptcy |
| Health-Chem Corporation | 07.0394 | Audit Concerns |
| HiEnergy Technologies, Inc. | 07.0395 | Miscellaneous |
| Innova Pure Water, Inc. | 07.0396 | Audit Concerns |
| International Commercial Television, Inc. | 07.0397 | Audit Concerns |
| Ista Pharmaceuticals, Inc. | 07.0398 | Loss/Deficit |
| Kid Castle Educational Corporation | 07.0399 | Audit Concerns |
| Le-Nature's, Inc. | 07.0400 | Section 363 Sales |
| Lexington Energy Services, Inc. | 07.0401 | Audit Concerns |
| MathStar, Inc. | 07.0402 | Loss/Deficit |
| Megola, Inc. | 07.0403 | Audit Concerns |
| Monogram Biosciences, Inc. | 07.0404 | Loss/Deficit |
| MTS, Inc. | 07.0405 | IP Asset Sale |

(Click on Reference Number to go directly to Company Profile)

| Company Name | Reference Number | Category Profile |
|-------------------------------------|-------------------------|------------------|
| Nanophase Technologies Corporation | 07.0406 | Loss/Deficit |
| New Medium Enterprises, Inc. | 07.0407 | Audit Concerns |
| OccuLogix, Inc. | 07.0408 | Audit Concerns |
| Panacos Pharmaceuticals, Inc. | 07.0409 | Loss/Deficit |
| Physicians Remote Solutions, Inc. | 07.0410 | Audit Concerns |
| Ply Gem Industries, Inc. | 07.0411 | Low Rating |
| Sand Technology, Inc. | 07.0412 | Loss/Deficit |
| SCOLR Pharma, Inc. | 07.0413 | Loss/Deficit |
| Somaxon Pharmaceuticals, Inc. | 07.0414 | Loss/Deficit |
| Stereotaxis, Inc. | 07.0415 | Loss/Deficit |
| Sun-Times Media Group, Inc. | 07.0416 | Loss/Deficit |
| Synthemed, Inc. | 07.0417 | Audit Concerns |
| Take-Two Interactive Software, Inc. | 07.0418 | Miscellaneous |
| TowerStream Corporation | 07.0419 | Audit Concerns |
| Tripos, Incorporated | 07.0420 | Miscellaneous |
| Unigene Laboratories, Inc. | 07.0421 | Audit Concerns |
| WorldGate Communications, Inc. | 07.0422 | Audit Concerns |

(Click on Reference Number to go directly to Company Profile)

Intellectual Property Prospector identifies companies with total assets of any size filing for bankruptcy or reporting other financial difficulty and profiles their ownership of intellectual property. The Prospector features companies that meet strictly defined, predetermined criteria and is designed to support the efforts of firms and individuals interested in identifying opportunities in the specific area of intellectual property, which includes patents, trademarks, trade secrets, and licenses, among others. Information is compiled weekly and the Prospector is distributed by email every Sunday evening to arrive before 9:00AM every Monday. The Prospector is published by Beard Group, Inc. (<http://BeardGroup.com>). For subscription information call Customer Service at 240-629-3300, ext. 27.

Prospector Profile Selection Criteria:

In order to appear in the **Intellectual Property Prospector**, a company must report ownership of intellectual property assets, as well as one of the conditions listed below:

- An event which indicates financial distress; e.g., default, distressed exchange offer, preferred dividend omission, debt at deep discount, restructuring, low rating, audit concerns, covenant problems, and loss/deficit.
- Chapter 11, 7, or 15 bankruptcy filing
- Section 363 Sales

DISCLAIMER: The conditions for inclusion in the Prospector are selected by the editors, because, in their opinion, the occurrence of such an event or the existence of such a circumstance is a likely indicator of current or prospective financial or operating difficulty. There are, however, other reasons why such facts or circumstances may exist. The inclusion of a profile suggests the possibility of financial distress or the possibility that the company may be of interest to firms and individuals interested in identifying intellectual property for some other reason. *Inclusion should not be construed to represent analysis of the condition of the company or its intellectual property or a definitive determination that the company is in difficulty.*

ACCURACY & COVERAGE: The information contained herein is obtained from sources believed to be reliable. However, the accuracy of most data cannot be verified prior to publication, and the information is not guaranteed. Desired information is often incomplete, inaccurate, delayed or unavailable. Do not rely on the Prospector without independent verification.

SUBSCRIPTIONS: Subscription rate: \$575 for six months, payable in advance. All subscriptions entered are continued until canceled. For subscription information call Customer Service at (240) 629-3300, ext. 27.

Intellectual Property Prospector is a publication of **Beard Group, Inc.**, P. O. Box 4250, Frederick, MD 21705, (240) 629-3300, <http://www.beardgroup.com>. ISSN 1935-3901. Copyright 2007. All rights reserved. Publisher: Christopher Beard.

**Prospector
Profile
07.0378**

Advanced Cell Technology, Inc.

1201 Harbor Bay Parkway
Alameda, CA 94501
(510) 748-4900

| | | |
|-----------|-------|-----------|
| NAICS | | 325412 |
| Employees | | 40 |
| Revenue | (mil) | \$0.44 |
| Income | (mil) | (\$18.72) |
| Assets | (mil) | \$16.99 |
| Liability | (mil) | \$46.53 |

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Stonefield Josephson, Inc. raised substantial doubt about Advanced Cell Technology, Inc.'s ability to continue as a going concern after auditing the Company's consolidated financial statements for the fiscal years ended December 31, 2006, and 2005. The auditing firm pointed to the Company's minimal sources of revenue, substantial net losses, substantial monetary liabilities in excess of monetary assets, and accumulated deficits as of December 31, 2006. The Company posted a net loss of \$18,719,938 on revenues of \$440,842 for the fiscal year ended December 31, 2006, as compared with a net loss of \$9,393,778 on revenues of \$395,007 for the same period in 2005. As of December 31, 2006, the Company's balance sheet showed strained liquidity with \$9,092,359 in total current assets and \$19,036,442 in total current liabilities. The Company also had \$29,542,324 in stockholders' deficit and \$41,873,515 in accumulated deficit.

Intellectual Property: The Company currently owns or has exclusive license to over 30 patents and has over 280 patent applications pending worldwide in the field of regenerative medicine and stem cell therapy. It also has non-exclusive rights to a portfolio of patents and patent applications that support its core intellectual property. The Company protects proprietary information by the use of confidentiality agreements with employees, consultants and certain contractors. The Company seeks patent protection for inventions in core technologies and in ancillary technologies that support core technologies or which will provide a competitive advantage. [SEC Filing 10-KSB 03-16-07]

Description: The Company develops and commercializes human stem cell technology in the fields of regenerative medicine and stem cell therapy in the U.S.

Officers: William M. Caldwell (Chair, CEO & Dir.); Michael D. West (Pres., Chief Scientific Officer & Dir.); Ivan Wolkind (VP-Finance); James G. Stewart, Sr. (VP & CFO); Alan C. Shapiro (Dir.); Alan G. Walton (Dir.); Erkki Ruoslahti (Dir.)

Auditor: Stonefield Josephson, Inc.

Securities: Common Stock Symbol ACTC.OB; OTCBB;
47,232,136 common shares outstanding as of March 12, 2007.

[Return to top](#)

**Prospector
Profile
07.0379**

Advanced Viral Research Corporation

200 Corporate Boulevard South
Yonkers, NY 10701
(914) 376-7383

| | | |
|---------------------------------|-------|----------|
| NAICS | | 541710 |
| Employees | | 7 |
| Revenue | (mil) | \$0.00 |
| Income | (mil) | (\$3.85) |
| Assets | (mil) | \$1.36 |
| Liability | (mil) | \$0.17 |
| (for the year ended 12/31/2006) | | |

Category: Audit Concerns

Event: Rachlin Cohen & Holtz LLP raised substantial doubt about Advanced Viral Research Corporation's ability to continue as a going concern after auditing the Company's financial statements. The Company has suffered recurring losses from operations and is dependent upon the continued sale of its securities or obtaining debt financing for funds to meet its cash requirements.

Intellectual Property: Patent protection and trade secret protection are important to the Company's business. Its future will depend on the ability to maintain trade secret protection, obtain patents and operate without infringing the proprietary rights of others both in the United States and abroad. To date, the Company has been issued or granted 14 U.S. patents, two Australian patents and one Canadian patent. In addition, the Company currently has five patent applications pending with the U.S. Patent and Trademark Office and 16 foreign patent applications. [SEC Filing 10-K 03-12-07]

Description: The Company engages in the research and development of therapies primarily for viral diseases.

Officers: Eli Wilner (Chair); Stephen M. Elliston (Pres., CEO & Dir.); Martin Bookman (CFO & Sec.); Angelo S. Botter (Dir.); Roy S. Walzer (Dir.)

Auditor: Rachlin Cohen & Holtz LLP

Securities: Common Stock-Symbol ADVR.OB; OTC BB;
696,587,734 common shares outstanding as of March 8, 2007.

[Return to top](#)

**Prospector
Profile
07.0380**

Allos Therapeutics, Inc.

11080 Circlepoint Road, Suite 200
Westminster, CO 80020
(303) 426-6262

| | | |
|---------------------------------|-------|-----------|
| NAICS | | 541710 |
| Employees | | 59 |
| Revenue | (mil) | \$0.00 |
| Income | (mil) | (\$30.21) |
| Assets | (mil) | \$36.38 |
| Liability | (mil) | \$6.83 |
| (for the year ended 12/31/2006) | | |

Category: Loss/Deficit

Event: Allos Therapeutics, Inc. reported a net loss of \$30,212,470 for the year ended December 31, 2006, higher than the reported net loss of \$21,837,285 in 2004 and \$20,136,588 in 2005. As a result of its recurring losses, the Company has an accumulated deficit of \$208,559,376 at the end of fiscal year 2006. The Company also used cash for operating activities of \$25,146,840 for fiscal year 2006, higher than the \$17,734,900 last year and \$21,099,572 in 2004.

Intellectual Property: The Company obtained exclusive worldwide rights to a portfolio of patents related to allosteric hemoglobin modifier compounds from Center for Innovative Technology. This patent portfolio includes numerous issued patents in the United States, Europe, and Japan and pending patent applications in Canada related to the current EFAPROXYN applications. It also entered into an agreement with the University of Colorado Health Sciences Center, the University of Salford and Cancer Research Technology, under which the Company obtained exclusive worldwide rights to intellectual property surrounding a proprietary molecule known as RH1. It also entered into a license agreement with Memorial Sloan-Kettering Cancer Center, SRI International and Southern Research Institute, under which the Company obtained exclusive worldwide rights to several issued United States patents and equivalent foreign patent applications to develop and market any product derived from any formulation of PDX in connection with all diagnostic and therapeutic uses, including human and veterinary diseases. [SEC Filing 10-K 03-14-07]

Description: The Company engages in the development and commercialization of small molecule drugs for cancer treatments in the United States.

Officers: Stephen J. Hoffman (Chair); Paul L. Berns (Pres., CEO & Dir.); David C. Clark (Treas. & Controller); Michael D. Casey (Dir.); Stewart Hen (Dir.); Jonathan Leff (Dir.); Mark G. Edwards (Dir.); William R. Ringo (Dir.); Timothy P. Lynch (Dir.)

Auditor: PricewaterhouseCoopers LLP

Securities: Common Stock-Symbol ALTH; NasdaqGM;
65,817,148 common shares outstanding as of March 6, 2007.

[Return to top](#)

**Prospector
Profile
07.0381**

Altair Nanotechnologies, Inc.

204 Edison Way
Reno, NV 89502
(775) 856-2500

| | |
|---------------------------------|-----------|
| NAICS | 541710 |
| Employees | 77 |
| Revenue (mil) | \$4.32 |
| Income (mil) | (\$17.20) |
| Assets (mil) | \$43.12 |
| Liability (mil) | \$5.30 |
| (for the year ended 12/31/2006) | |

Category: Loss/Deficit

Event: Altair Nanotechnologies, Inc. reported a net loss of \$17,200,283 on revenues of \$4,323,960 for the fiscal year ended December 31, 2006, higher than the reported net loss of \$9,937,212 in 2005 and \$7,002,280 in 2004. As a result of its recurring losses, the Company has an accumulated deficit of \$80,353,188 as of December 31, 2006.

Intellectual Property: The Company has been awarded four U.S. and several international patents protecting its technology including: method for producing catalyst structures, method for producing mixed metal oxides and metal oxide compounds, processing for making lithium titanate, and method for making nano-sized and sub-micron-sized lithium-transition metal oxides. The U.S. patents expire in 2020, 2021 and 2022. In addition, two new patent applications have recently been filed. [SEC Filing 10-K 03-13-07]

Description: The Company engages in developing and commercializing nanomaterial and titanium dioxide pigment technologies.

Officers: Alan J. Gotcher (Pres., CEO & Dir.); Edward Dickinson (CFO & Sec.); Michel Bazinet (Dir.); John Bengtson (Dir.); George Hartman (Dir.); James I. Golla (Dir.); Pierre Lortie (Dir.); Christopher E. Jones (Dir.)

Auditor: Perry-Smith LLP

Securities: Common Stock-Symbol ALTI; NasdaqCM;
69,999,793 common shares outstanding as of March 5, 2007.

[Return to top](#)

**Prospector
Profile
07.0382**

American Leisure Holdings, Inc.

2460 Sand Lake Road
Orlando, FL 32809
(407)-251-2240

| | | |
|---------------------------------|-------|----------|
| NAICS | | 561500 |
| Employees | | 84 |
| Revenue | (mil) | \$19.38 |
| Income | (mil) | (\$4.13) |
| Assets | (mil) | \$89.92 |
| Liability | (mil) | \$83.70 |
| (for the year ended 12/31/2005) | | |

Category: Audit Concerns

Event: Lopez, Blevins, Bork & Associates LLP raised substantial doubt about American Leisure Holdings, Inc.'s ability to continue as a going concern after auditing the Company's consolidated financial statements for the fiscal year ended December 31, 2005. The auditing firm pointed to the Company's recurring losses from operations and the need to raise additional financing in order to satisfy its creditors and execute its business plan. The Company posted a net loss of \$4,126,779 on revenues of \$19,381,284 for the fiscal year ended December 31, 2005, as compared with a net loss of \$6,634,301 on revenues of \$6,419,320 for the same period in 2004. As of December 31, 2005, the Company's balance sheet showed strained liquidity with \$11,054,971 in total current assets and \$12,764,605 in total current liabilities.

Intellectual Property: The Company has filed for a trademark, Serial Number 78611764, for the service mark "Traveleaders." [SEC Filing 10-KSB/A 03-16-07]

Description: The Company develops vacation real estate in Orlando, Florida and also provides a range of business and vacation travel services.

Officers: Malcolm J. Wright (Chair, CEO, & CFO); Frederick Pauzar (Pres., COO, & Dir.); L. William Chiles (Dir.);

Auditor: Lopez, Blevins, Bork & Associates LLP

Securities: Common Stock Symbol AMLH.OB; OTC BB;
10,642,974 common shares outstanding as of August 18, 2006.

[Return to top](#)

**Prospector
Profile
07.0383**

Aquatic Cellulose International Corporation

NAICS

211111

331 4th Street
Salmon Arm, British Columbia V1E 4P2
Canada
(250) 833-1985

| | | |
|--------------------------------|-------|----------|
| Revenue | (mil) | \$0.46 |
| Income | (mil) | (\$5.11) |
| Assets | (mil) | \$1.47 |
| Liability | (mil) | \$11.09 |
| (for the year ended 5/31/2006) | | |

Category: Audit Concerns

Event: Peterson Sullivan PLLC raised substantial doubt about Aquatic Cellulose International Corporation's ability to continue as a going concern because it has not generated positive cash flows from operations and has an accumulated deficit at May 31, 2006.

Intellectual Property: In October 2006, the Company purchased from former CEO Gary Ackles all rights, title and interest to the TigeroLynk™ patents, blueprints, drawings and concepts for \$250,000. The Company believes that this technology represents a significant addition to the systems used in the off-shore oil and natural gas industry. [SEC Filing 10-KSB 03-13-07]

Description: The Company is engaged in oil and gas investment, development and production operating principally in the United States.

Officers: Sheridan B. Westgarde (Pres. & Dir.)

Auditor: Peterson Sullivan PLLC

Securities: Common Stock-Symbol AQCI.PK; PNK;
100,000,000 common shares outstanding as of March 8, 2007.

[Return to top](#)

**Prospector
Profile
07.0384**

Bally Total Fitness Holding Corp.

8700 West Bryn Mawr Ave.
Chicago, IL 60631
(773) 380-3000

| | | |
|---------------------------------|-------|------------|
| NAICS | | 713940 |
| Employees | | 21,600 |
| Revenue | (mil) | \$1,071.03 |
| Income | (mil) | (\$9.61) |
| Assets | (mil) | \$480.09 |
| Liability | (mil) | \$1,943.78 |
| (for the year ended 12/31/2005) | | |

Category: Miscellaneous

Event: Shares of Bally Total Fitness Holding Corp. lost more than half their value, according to various news reports. The plunge was due to the Company's disclosure that it was considering bankruptcy as an option. The Company's stock plummeted 62%, or \$1.24, to close at its all-time low of 75 cents a share on the New York Stock Exchange.

Intellectual Property: The majority of Bally Total Fitness Holding Corp.'s fitness centers use the service mark "Bally Total Fitness®." Other facilities operate under the names "Bally Sports Clubs®" and the "The Sports Clubs of Canada®". The Company operated facilities under the "Crunch Fitness" and the "Gorilla Sports" brands until January 20, 2006, when it completed the sale of the Crunch Fitness business, including the Crunch Fitness and Gorilla Sports brands. The Company operated several fitness centers under the "Pinnacle Fitness®" brand until May 1, 2006, when it converted those clubs to "Bally" clubs. The use of trademarks and service marks enhances brand identity and increases advertising efficiencies. [SEC Filing 10-K 06-27-06]

Description: The Company is a commercial operator of fitness centers in North America.

Officers: Don R. Kornstein (Chair); Julie Adams (SVP); Marc D. Bassewitz (SVP & Gen. Counsel); William G. Fanelli (SVP); Gail J. Holmberg (SVP & Chief Info. Officer); Thomas S. Massimino (SVP); James A. McDonald (SVP & Chief Mktg. Officer); John H. Wildman (SVP & COO); Harold Morgan (SVP & Chief Admin. Officer); Ronald G. Eidell (SVP & CFO); Barry R. Elson (Interim CEO & Dir.); Charles J. Burdick (Dir.); Eric Langshur (Dir.); John W. Rogers, Jr. (Dir.); Steven S. Rogers (Dir.)

Auditor: KPMG LLP

Securities: Common Stock-Symbol BFT; NYSE;
41,315,263 common shares outstanding as of July 31, 2006.
10 1/2% senior notes due 2011.

[Return to top](#)

**Prospector
Profile
07.0385**

Bionovo, Inc.

5858 Horton Street, Suite 375
Emeryville, CA 94608
(510) 601-2000

| | | |
|---------------------------------|-------|----------|
| NAICS | | 541710 |
| Employees | | 19 |
| Revenue | (mil) | \$0.02 |
| Income | (mil) | (\$5.62) |
| Assets | (mil) | \$4.97 |
| Liability | (mil) | \$1.48 |
| (for the year ended 12/31/2006) | | |

Category: Loss/Deficit

Event: Bionovo, Inc. reported a net loss of \$5,617,800 on revenues of \$15,000 for the year ended December 31, 2006, a sharp increase compared to last year's \$3,637,530 net loss on \$15,000 of revenues. As a result of its recurring losses, the Company has an accumulated deficit of \$9,848,967 as of December 31, 2006.

Intellectual Property: The Company has filed four patent applications with the United States Patent & Trademark Office and one patent application with the Taiwan Intellectual Property Office related to its drug candidates. Its competitive position is also dependent on unpatented trade secrets. The Company intends to implement a policy of requiring employees, consultants and advisors to execute proprietary information and invention assignment agreements upon commencement of employment or consulting relationships. [SEC Filing 10-KSB 03-14-07]

Description: The Company engages in the discovery and development of drugs in the areas of cancer and women's health primarily in the United States.

Officers: Isaac Cohen (Chair, Pres. & CEO); James P. Stapleton (CFO); Mary Tagliaferri (VP, Sec., Treas. & Dir.); David Naveh (Dir.) Michael Vanderhoof (Dir.); Brooks Corbin (Dir.); Frances W. Preston (Dir.)

Auditor: PMB Helin Donovan, LLP

Securities: Common Stock-Symbol BNVI.OB; OTC BB;
63,720,224 common shares outstanding as of February 28, 2007.

[Return to top](#)

**Prospector
Profile
07.0386**

BTX Holdings, Inc.
1400 Cypress Creek Road
Fort Lauderdale, FL 33309
(954) 776-6600

| | | |
|---------------------------------|-------|----------|
| NAICS | | 562219 |
| Employees | | 3 |
| Revenue | (mil) | \$0.00 |
| Income | (mil) | (\$0.74) |
| Assets | (mil) | \$0.01 |
| Liability | (mil) | \$0.63 |
| (for the year ended 12/31/2006) | | |

Category: Audit Concerns

Event: Webb & Company PA expressed substantial doubt about BTX Holdings, Inc.'s ability to continue as a going concern after auditing the Company's financial statements. The auditor points out that the Company has had net losses of \$2,094,639 from inception, a negative cash flow from operations of \$928,827 from inception, a working capital deficiency of \$629,209 and a stockholders' deficiency of \$622,041.

Intellectual Property: The Company relies on a combination of patent, trade secrets and know-how to establish and protect proprietary rights to its technologies and products. In May, 2005, the Company obtained the exclusive ownership to Method and Process Patent #7,060,313, which was granted on June 13, 2006. The patent relates to the separation of various organic streams from citrus waste and all related products. Additionally, the Company acquired the CITRASORB trademark (reg. no. 2711964) and CITRAFIBER trademark (reg. no. 2830419). In December 2005, the Company entered into an agreement to acquire the exclusive ownership to Method and Process European Patent Pending #5425221.8. The patent relates to the separation of basic elements and molecular components from various organic and inorganic feedstocks. [SEC Filing 10-KSB 03-09-07]

Description: The Company acquires, develops, and deploys technologies to process plant derived biomass waste, extract the usable fractions, and utilize or sell the extractions in further secondary processes in the United States.

Officers: Scott Silverman (Chair, Pres., CEO & CFO)

Auditor: Webb & Company PA

Securities: Common Stock-Symbol BTXO.OB; OTC BB;
34,043,020 common shares outstanding as of March 9, 2007.

[Return to top](#)

**Prospector
Profile
07.0387**

Claimsnet.com, Inc.

14860 Montfort Drive, Suite 250
Dallas, TX 75254
(972) 458-1701

| | |
|---------------------------------|----------|
| NAICS | 511210 |
| Employees | 12 |
| Revenue (mil) | \$1.46 |
| Income (mil) | (\$0.39) |
| Assets (mil) | \$0.73 |
| Liability (mil) | \$1.82 |
| (for the year ended 12/31/2006) | |

Category: Audit Concerns

Event: Whitley Penn LLP expressed doubt on Claimsnet.com, Inc.'s ability to continue as a going concern after auditing its financial statements. The Company has generated losses since inception, incurred negative cash flows from operations, and has a working capital and stockholders' deficit at December 31, 2006. Additionally, management does not believe that available cash resources, anticipated revenues from operations or proceeds from financing activities and funding commitments will be sufficient to satisfy the Company's near term capital requirements.

Intellectual Property: The Company holds no patents and relies on a combination of trade secrets and copyright laws, non-disclosure, and other contractual agreements and technical measures to protect rights in technological know-how and proprietary services. In addition, the Company has been advised that trademark and service mark protection of its corporate name is not available. The Company depends upon confidentiality agreements with officers, directors, employees, consultants, and subcontractors to maintain the proprietary nature of its technology. [SEC Filing 10-KSB 03-08-07]

Description: The Company engages in the ownership, operation, and licensing of software used for processing medical insurance claims on the Internet.

Officers: Don Crosbie (Chair, Pres. & CEO); Alfred Dubach (Vice Chair); Laura M. Bray (CFO); Gary J. Austin (COO); K. Scott Spurlock (VP-Dev't.); John C. Willems, III (Dir.); Thomas Michel (Dir.)

Auditor: Whitley Penn LLP

Securities: Common Stock-Symbol CLAI.OB; OTC BB;
26,001,180 common shares outstanding as of March 8, 2007.

[Return to top](#)

**Prospector
Profile
07.0388**

DNAPrint Genomics, Inc.
1621 West University Parkway
Sarasota, FL 34243
(941) 366-3400

| | | |
|---------------------------------|-------|-----------|
| NAICS | | 541710 |
| Employees | | 24 |
| Revenue | (mil) | \$2.43 |
| Income | (mil) | (\$12.35) |
| Assets | (mil) | \$10.27 |
| Liability | (mil) | \$13.98 |
| (for the year ended 12/31/2006) | | |

Category: Audit Concerns

Event: Pender Newkirk & Co. expressed doubt about DNAPrint Genomics, Inc.'s ability to continue as a going concern after auditing the Company's financial statements for the year ended December 31, 2006. The Company has recurring losses from operations, a working capital deficit, and needs a significant amount of capital financing to proceed with its business plan.

Intellectual Property: The Company has filed claims for international and domestic patent protection. The patents, if issued, will help ensure protection of bioinformatics platforms, analytical software, genome maps and genetic classifiers in forensic, consumer products, and pharmacogenomics applications. The most significant patent applications cover the bioinformatics platforms and genome maps. Other applications describe the mathematical process of finding complex genetic information and the actual processes that find the gene variants responsible for specific complex genetic traits. Five of its patent applications have entered national phases and are pending review. The pigmentation patent is important because it includes the methods and compositions for determining skin shade, eye color or any other pigmentation application. The Statin patent application includes the use of method for determining a person's ability to respond favorably to a particular statin drug, not the class as a whole. [SEC Filing 10-KSB 03-15-07]

Description: The Company develops genomics-based products and services primarily in biomedical and forensics markets in the U.S. Its subsidiaries include Biofrontera AG and Trace Genetics.

Officers: Hector Gomez (Chair, Chief Medical Officer & Dir.); Richard Gabriel (Pres., CEO, & Dir.); Karen L. Surplus (CFO & Principal Acctg. Officer); Tony Frudakis (Chief Scientific Officer & Dir.)

Auditor: Pender Newkirk & Co.

Securities: Common Stock Symbol DNAG.OB; OTCBB;
492,844,374 common shares outstanding as of February 15, 2007.

[Return to top](#)

**Prospector
Profile
07.0389**

eLEC Communications Corporation

75 South Broadway, Suite 302
White Plains, NY 10601
(914) 682-0214

| | | |
|---------------------------------|-------|----------|
| NAICS | | 517000 |
| Employees | | 35 |
| Revenue | (mil) | \$8.36 |
| Income | (mil) | (\$2.35) |
| Assets | (mil) | \$4.19 |
| Liability | (mil) | \$8.44 |
| (for the year ended 11/30/2006) | | |

Category: Audit Concerns

Event: Nussbaum Yates & Wolpov PC expressed doubt on eLEC Communications Corporation's ability to continue as a going concern after auditing the Company's financial statements. The Company has suffered recurring losses from operations and is in default of its financing agreements with its principal lender.

Intellectual Property: The Company relies on unpatented trade secrets and know-how to maintain competitive position. Its inability to protect these secrets and know-how could have a material adverse effect on its business and prospects. The Company protects proprietary information by entering into confidentiality agreements with employees and consultants and business partners. [SEC Filing 10-K 03-07-07]

Description: The Company, through its subsidiaries, offers telecommunications products and services in the United States.

Officers: Paul H. Riss (Chair & CEO); Mark Richards (Pres. & CIO); Michael Khalilian (CTO); Ron Harden (EVP-Sales)

Auditor: Nussbaum Yates & Wolpov PC

Securities: Common Stock-Symbol ELEC.OB; OTC BB;
22,434,282 common shares outstanding as of February 15, 2007.

[Return to top](#)

**Prospector
Profile
07.0390**

eMerge Interactive, Inc.

10305 - 102nd Terrace
Sebastian, FL 39258
(772) 581-9700

| | | |
|---------------------------------|-------|----------|
| NAICS | | 561910 |
| Employees | | 24 |
| Revenue | (mil) | \$1.87 |
| Income | (mil) | (\$7.39) |
| Assets | (mil) | \$5.40 |
| Liability | (mil) | \$1.94 |
| (for the year ended 12/31/2005) | | |

Category: Section 363 Sales

Event: eMerge Interactive, Inc. disclosed that on March 15, 2007, the U.S. Bankruptcy Court for the Southern District of Florida entered two sales orders approving the sales of substantially all of the assets of the Company's CattleLog and VerifEYE business units. Origin Micro Systems, LLC will purchase CattleLog assets for approximately \$1,600,000 while Chad, Inc. will purchase the VerifEYE assets for approximately \$370,000.

Intellectual Property: The Company currently has multiple U.S. and foreign patent applications that are pending before the U.S. Patent and Trademark Office and related foreign agencies regarding livestock management systems and methods. U.S. patent number 5,914,247 is licensed from the Iowa State University Research Foundation (ISURF) and the USDA under a license agreement entered into in August 1999. U.S. patent numbers 6,198,107 and 6,512,236 are licensed from Clare Chemical Research, Inc. under a license agreement entered into in May 2005. The Company's FST business is highly dependent on continued maintenance of these licenses. These trademarks have been registered with the U.S. Patent and Trademark Office: eMerge Interactive®, VerifEYE® and CattleLog®. Additionally, the Company has a number of foreign trademarks both pending and registered. [SEC Filing 10-K 03-30-06]

Description: The Company provides products and services focused on food safety technology and livestock management software. The Company filed for Chapter 11 protection on February 14, 2007, with the U.S. Bankruptcy Court for the Southern District of Florida, case number 07-10932, before Judge Steven H. Friedman.

Officers: David C. Warren (Pres. & CEO); Robert Drury (EVP); Susan D. Mermer (EVP & CFO); Mark S. Fox (EVP); William Mies (VP)

Auditor: KPMG LLP

Attorneys: Jimmy D. Parrish, Esq., at Latham, Shuker, Barker, Eden & Beaudine, LLP; Orlando, FL; (407) 481-5800

Securities: 4,030,579 common shares outstanding as of November 7, 2006.

[Return to top](#)

**Prospector
Profile
07.0391**

Encysive Pharmaceuticals, Inc.

4848 Loop Central Drive, Suite 700
Houston, TX 77081
(713) 796-8822

| | | |
|---------------------------------|-------|------------|
| NAICS | | 325412 |
| Employees | | 282 |
| Revenue | (mil) | \$19.00 |
| Income | (mil) | (\$109.28) |
| Assets | (mil) | \$63.14 |
| Liability | (mil) | \$156.85 |
| (for the year ended 12/31/2006) | | |

Category: Audit Concerns

Event: KPMG LLP expressed substantial doubt about Encysive Pharmaceuticals, Inc.'s ability to continue as a going concern after auditing the Company's consolidated financial statements for the year ended December 31, 2006. The firm pointed to the Company's recurring losses from operations and net capital deficiency. The Company posted a net loss of \$109,283,000 on revenues of \$18,995,000 for the year ended December 31, 2006. The Company's balance sheet showed \$93,717,000 in stockholders' deficit and \$422,278,000 in accumulated deficit.

Intellectual Property: Because of the length of time and expense associated with developing new pharmaceutical products, the Company places considerable importance on intellectual property protection for new technologies, compounds, products and processes. The Company actively seeks patent protection both in the United States and internationally and files additional patent applications to cover improvements to its compounds, products and processes. The Company also relies on trade secrets, internal know-how, technological innovations and agreements with third parties to develop, maintain and protect competitive position and to develop its business. The Company currently has 6 patents registered with the US Patent & Trademark Office. [SEC Filing 10-K 03-16-07]

Description: The Company discovers, develops, and commercializes novel, synthetic, small-molecule compounds for the treatment and prevention of a variety of cardiovascular, vascular and related inflammatory diseases.

Officers: John M. Pietruski (Chair); Bruce D. Given (Pres., CEO, & Dir.); Richard A.F. Dixon (SVP, Chief Scientific Officer, & Dir.); George W. Cole (COO); Gordon H. Busenbark (CFO); Ron J. Anderson (Dir.); J. Kevin Buchi (Dir.); Robert J. Cruikshank (Dir.); John H. Dillon II (Dir.); Suzanne Oparil (Dir.); James A. Thomson (Dir.); James T. Willerson (Dir.)

Auditor: KPMG LLP

Securities: Common Stock Symbol ENCY; NasdaqGM;
62,507,490 common shares outstanding as of February 28, 2007.
2.50% convertible senior notes due on 2012

[Return to top](#)

**Prospector
Profile
07.0392**

Flexpoint Sensor Systems, Inc.

106 West Business Park Drive
Draper, UT 84020
(801) 568-5111

| | | |
|---------------------------------|-------|----------|
| NAICS | | 541710 |
| Employees | | 11 |
| Revenue | (mil) | \$0.10 |
| Income | (mil) | (\$2.51) |
| Assets | (mil) | \$8.79 |
| Liability | (mil) | \$0.05 |
| (for the year ended 12/31/2006) | | |

Category: Audit Concerns

Event: Hansen, Barnett & Maxwell, P.C. raised substantial doubt about Flexpoint Sensor Systems, Inc.'s ability to continue as a going concern after auditing the Company's financial statements. The Company has not earned any appreciable revenue, has suffered net losses and has had negative cash flows from operating activities since inception.

Intellectual Property: The Company regards certain designs as proprietary and attempts to protect them with patents and by restricting disclosure of the designs as trade secrets. The Company has nine issued patents for its Bend Sensor® technology. It has filed five additional patent applications, and are in the process of preparing two additional patents for new types of sensors. The Company's Sensitron subsidiary also owns seven United States patents and two foreign patents related to the Bend Sensor® technology. [SEC Filing 10-K 03-14-07]

Description: The Company engages in the design, engineering, and manufacture of sensor technology and equipment using flexible potentiometer technology, known as Bend Sensor technology.

Officers: John A. Sindt (Chair & CFO); Clark M. Mower (Pres., CEO & Dir.); B. Fred Atkinson, Jr. (Sec., Treas & Comptroller); Ruland J. Gill, Jr. (Dir.)

Auditor: Hansen, Barnett & Maxwell, P.C.

Securities: Common Stock-Symbol FLXT.OB; OTC BB;
23,292,887 common shares outstanding as of February 22, 2007.

[Return to top](#)

**Prospector
Profile
07.0393**

Hancock Fabrics, Inc.

One Fashion Way
Baldwyn, MS 38824
(662) 365-6000

| | | |
|--------------------------------|-------|-----------|
| NAICS | | 424310 |
| Employees | | 6,000 |
| Revenue | (mil) | \$403.24 |
| Income | (mil) | (\$30.25) |
| Assets | (mil) | \$241.97 |
| Liability | (mil) | \$161.41 |
| (for the year ended 1/28/2006) | | |

Category: Bankruptcy

Event: Hancock Fabrics, Inc. and its debtor-affiliates filed for Chapter 11 protection on March 21, 2007, with the U.S. Bankruptcy Court for the District of Delaware (Delaware), lead case number 07-10353, before Judge Brendan Linehan Shannon.

Intellectual Property: The Company has registered the service mark "Hancock Fabrics" with the United States Patent and Trademark Office. [SEC Filing 10-K 01-05-07]

Description: Hancock Fabrics, Inc. is a retailer of specialty fashion and home decorating textiles, sewing accessories, needlecraft supplies and sewing machines.

Officers: Jane F. Aggers (Pres. & CEO); Bruce D. Smith (EVP, CFO, & Treas.); Dean W. Abraham (SVP); Clayton E. Stallings (SVP); William A. Sheffield (SVP); William D. Smothers (SVP); Wellford L. Sanders (Dir.); Don L. Fruge (Dir.); Roger T. Knox (Dir.); Donna L. Weaver (Dir.); Bernard J. Wein (Dir.); Bernard J. Wein (Dir.)

Auditor: PricewaterhouseCoopers LLP

Attorneys: Morris, Nichols, Arshat & Tunnell; Wilmington, DE; (302) 658-9200
Gregory Thomas Donilon, Esq.
Robert J. Dehney, Esq.
Derek C. Abbott, Esq.
Curtis S. Miller, Esq.

Securities: Common Stock Symbol HKFIQ.PK; PNK;
19,310,892 common shares outstanding as of November 30, 2006.

[Return to top](#)

**Prospector
Profile
07.0394**

Health-Chem Corporation

101 Sinking Springs Lane
Emigsville, PA 17318
(717) 764-1191

| | | |
|---------------------------------|-------|----------|
| NAICS | | 541710 |
| Employees | | 52 |
| Revenue | (mil) | \$7.59 |
| Income | (mil) | (\$2.48) |
| Assets | (mil) | \$6.97 |
| Liability | (mil) | \$21.90 |
| (for the year ended 12/31/2005) | | |

Category: Audit Concerns

Event: Demetrius & Company LLC raised substantial doubt about Health-Chem Corporation's ability to continue as a going concern after auditing the Company's amended financial statements. The auditor points out that the Company is in default of payments to bondholders and licensors, and has working capital deficiencies.

Intellectual Property: The Company has obtained 11 US and foreign patents and trademarks relating to its transdermal delivery systems and manufacturing processes. While it views the patents and trademarks as valuable assets, it does not consider any single patent or trademark to be of material importance to the business as a whole. [SEC Filing 10-KSB 03-08-07]

Description: The Company manufactures controlled release products to deliver drugs topically or transdermally.

Officers: Andy E. Yurowitz (Chair, Pres. & CEO); Ronald J. Burghauer (CFO, Sec. & Treas.); Andrew J. Levinson (Dir.); Manfred Mayerfeld (Dir.)

Auditor: Demetrius & Company LLC

Securities: Common Stock-Symbol HCLC.PK; PNK;
11,443,424 common shares outstanding as of February 13, 2007.

[Return to top](#)

**Prospector
Profile
07.0395**

HiEnergy Technologies, Inc.

1601 Alton Parkway Unit B
Irvine, CA 92606
(949) 757-0855

| | | |
|-----------|-------|----------|
| NAICS | | 541710 |
| Employees | | 17 |
| Revenue | (mil) | \$0.00 |
| Income | (mil) | (\$8.63) |
| Assets | (mil) | \$1.78 |
| Liability | (mil) | \$4.51 |

(for the year ended 4/30/2006)

Category: Miscellaneous

Event: HiEnergy Technologies, Inc.'s Board of Directors authorized the Company and its subsidiaries to file for voluntary protection under the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the Central District of California. The action was taken in order to protect the company's operations and assets while it works to resolve its financial and business challenges.

Intellectual Property: The Company has filed eight patent applications and one provisional patent application with the U.S. Patent and Trademark Office. Over the past years, the Company has developed proprietary software, comprised of an advanced analytical engine, complex decoding algorithms and a special purpose operator interface. As part of confidentiality procedures, the Company requires employees and consultants to enter into standard agreements pursuant to which the employee and consultant agrees to keep confidential all proprietary information and to assign all rights in any proprietary information or technology made by the employee or consultant during his or her employment. [SEC Filing 10-KSB 09-15-06]

Description: The Company engages in the research, design, testing, and development of its proprietary stoichiometric sensor devices and underlying technologies.

Officers: William A. Nitze (Chair); Peter J. Le Beau (Vice Chair); Roger W.A. Spillmann (Pres., CEO, Sec., Treas. & Dir.); David R. Baker (Dir.); Col. William J. Lacey, Jr. (Dir.); Dr. Bogdan C. Maglich (Dir.)

Auditor: Singer Lewak Greenbaum & Goldstein LLP

Securities: Common Stock-Symbol HIET.OB; OTC BB;
68,851,390 common shares outstanding as of December 20, 2006.

[Return to top](#)

**Prospector
Profile
07.0396**

Innova Pure Water, Inc.

4951 Airport Parkway, Suite 500
Addison, TX 75001
(972) 980-0486

| | | |
|--------------------------------|-------|----------|
| NAICS | | 333319 |
| Employees | | 5 |
| Revenue | (mil) | \$0.53 |
| Income | (mil) | (\$0.51) |
| Assets | (mil) | \$0.99 |
| Liability | (mil) | \$0.80 |
| (for the year ended 6/30/2006) | | |

Category: Audit Concerns

Event: Turner, Stone & Company, LLP expressed doubt on Innova Pure Water, Inc.'s ability to continue as a going concern after auditing the Company's financial statements. The auditor notes that the Company has negative working capital of \$251,800 as of June 30, 2005 and has incurred substantial operating losses resulting in an accumulated deficit of \$3,318,100.

Intellectual Property: The Company currently has rights to over 40 issued or pending patents which are specifically related to consumer water treatment products. The Company's Numera Software Corporation subsidiary owns software that is protected under U.S. copyright and trademark laws and international treaties. [SEC Filing 10-KSB 11-01-06]

Description: The Company is a pioneer in the field of water purification technology as well as a supplier of patent protected water filtration products for the consumer and outdoor markets.

Officers: John E. Nohren, Jr. (Chair); David L. Zich (Pres. & Dir.); Rose C. Smith (Dir); David Paul Condra (Dir); Jim R. Davisson (CFO, Sec., Treas. & Dir.); John L. Finan (Dir); Randal McClanahan (Dir)

Auditor: Turner, Stone & Company, LLP

Securities: Common Stock-Symbol IPURE.OB; OTC BB;
34,804,236 common shares outstanding as of December 31, 2006.

[Return to top](#)

**Prospector
Profile
07.0397**

| | | | |
|---|-----------|--------|--------|
| International Commercial Television, Inc. 10245 Sunrise Place NE Bainbridge Island, WA 98110 (206) 842-3729 | NAICS | 541840 | |
| | Employees | 3 | |
| | Revenue | (mil) | \$2.42 |
| | Income | (mil) | \$0.41 |
| | Assets | (mil) | \$0.56 |
| | Liability | (mil) | \$1.45 |

(for the year ended 12/31/2005)

Category: Audit Concerns

Event: Dohan & Company PA raised doubts on International Commercial Television, Inc.'s ability to continue as a going concern after auditing the Company's financial statements. The Company has generated negative cash flows from operating activities during the past year and has experienced recurring losses from operations. In addition, the Company has a working capital deficiency of approximately \$320,000 and an accumulated deficit of approximately \$1,286,000 as of December 31, 2005.

Intellectual Property: The Company has several registered trademarks for BetterBlocks™ in countries throughout the world and Derma Wand™, Smart Stacks™ and TwinTech™ in the United States. The Company also has patents for the toy building elements of BetterBlocks™ in several countries throughout the world. It has non-exclusive rights to use the patent for Derma Wand™ and a patent for a unique cooking device. The Company has copyright registrations for all versions of infomercials for BetterBlocks™ and Smart Stacks™. It also has registered designs for BetterBlocks™ in several countries throughout the world. [SEC Filing 10-KSB/A 03-09-07]

Description: The Company produces long-form and short-form infomercials in the United States and internationally.

Officers: Kelvin Claney (Pres., CEO, Sec. & Dir.); Karl Redekopp (CFO); William R. Flohr (Dir.)

Auditor: Dohan & Company PA

Securities: Common Stock-Symbol ICTL.OB; OTC BB;
10,635,188 common shares outstanding as of March 30, 2006.

[Return to top](#)

**Prospector
Profile
07.0398**

Ista Pharmaceuticals, Inc.

15295 Alton Parkway
Irvine, CA 92618
(949) 788-6000

| | | |
|---------------------------------|-------|-----------|
| NAICS | | 423450 |
| Employees | | 198 |
| Revenue | (mil) | \$33.01 |
| Income | (mil) | (\$38.42) |
| Assets | (mil) | \$59.74 |
| Liability | (mil) | \$64.30 |
| (for the year ended 12/31/2006) | | |

Category: Loss/Deficit

Event: Ista Pharmaceuticals, Inc. posted a net loss of \$38,419,000 on revenues of \$33,007,000 for the fiscal year ended December 31, 2006, as compared with a net loss of \$38,480,000 on revenues of \$10,660,000 in 2005. As of December 31, 2006, the Company's balance sheet showed \$4,559,000 in stockholders' deficit and \$264,962,000 in accumulated deficit.

Intellectual Property: The Company's success will depend on its ability to obtain patent protection for inventions, to preserve trade secrets and to operate without infringing the proprietary rights of third parties. It currently owns or licenses 32 United States and foreign patent applications and 96 United States and foreign issued patents. The Company seeks protection of trade secrets and proprietary know-how, in part, through confidentiality and proprietary information agreements. The Company also files trademark applications to protect the names of products. [SEC Filing 10-K 03-16-07]

Description: The Company engages in the development and commercialization of ophthalmic products for serious eye diseases and conditions.

Officers: Richard C. Williams (Chair); Vicente Anido, Jr. (Pres., CEO, & Dir.); Lauren P. Silvernail (VP & CFO); Peter Barton Hutt (Dir.); Kathleen D. LaPorte (Dir.); Benjamin F. McGraw III (Dir.); Dean J. Mitchell (Dir.); Andrew J. Perlman (Dir.); Wayne I. Roe (Dir.)

Auditor: Ernst & Young LLP

Securities: Common Stock Symbol ISTA; NasdaqGM;
26,211,160 common shares outstanding as of March 1, 2007.
8% senior subordinated convertible notes which mature on June 2011.

[Return to top](#)

**Prospector
Profile
07.0399**

Kid Castle Educational Corporation

8th Floor, No. 98 Min Chuan Road
Taipei, Taiwan, Republic of China
(011) 886-2-2218-5996

| | | |
|---------------------------------|-------|----------|
| NAICS | | 541930 |
| Employees | | 175 |
| Revenue | (mil) | \$10.23 |
| Income | (mil) | (\$1.70) |
| Assets | (mil) | \$10.98 |
| Liability | (mil) | \$12.28 |
| (for the year ended 12/31/2005) | | |

Category: Audit Concerns

Event: Brock Schechter & Polakoff, LLP raised doubts on Kid Castle Educational Corporation's ability to continue as a going concern due to its recurring losses from operations and net capital deficiency.

Intellectual Property: The name "Kid Castle" and various drawings used in materials are trademarked and registered in Taiwan and the People's Republic of China. The Company's copyrights, trademarks, service marks, trade secrets, proprietary technology, and other intellectual property rights distinguishes its products and services from those of competitors and contributes to competitive advantage in target markets. [SEC Filing 10-K 03-08-07]

Description: The Company is a leading provider in the People's Republic of China and Republic of China of English-language instruction and educational services to children for whom Chinese is the primary language.

Officers: Suang Yi Pai (Chair, Acting CFO & Dir.); Min Tan Yang (CEO & Dir.); Chin Chen Huang (Dir.); Ming Tsung Shih (Dir.); Robert Theng (Dir.)

Auditor: Brock Schechter & Polakoff, LLP

Securities: Common Stock-Symbol KDCE.PK; PNK;
18,999,703 common shares outstanding as of December 31, 2006.

[Return to top](#)

**Prospector
Profile
07.0400****Le-Nature's, Inc.**

11 Lloyd Ave.
Latrobe, PA 15650
(724) 532-0600

NAICS

312112

Category: Section 363 Sales

Event: The U.S. Bankruptcy Court for the Western District of Pennsylvania gave R. Todd Nielson, the Chapter 11 Trustee in Le Nature's, Inc. and its debtor-affiliates' bankruptcy cases, authority to employ Gordon Brothers Industrial LLC and Harry Davis & Company as his exclusive sales agent for the turnkey sale of real and personal property relating to the Debtors' bottling operations and warehouse facilities in Latrobe, Pennsylvania. The Trustee believes the value of the Assets will be higher to a turnkey buyer who can recommence production for the summer months, if possible, during which the demand for bottled water and soft drinks is at its peak.

Intellectual Property: The Company has registered with the United States Patent and Trademark Office several names used in its products including: ICE™ Water, Dazzler™ Fruit Juice Drinks and Lemonade, AquaAde™ and AQUA Xtra™. [Company Website]

Description: The Company manufactures and sells flavored bottled water and a line of premium beverages. The Company filed for Chapter 11 protection with the Bankruptcy Court for the Western District of Pennsylvania on November 1, 2006, case number 06-25454.

Officers: Gregory J. Podlucky (Chair & CEO); Jonathan E. Podlucky (COO); David E. Getzik (CFO); Robert B. Lynn (EVP)

Attorneys: Dean Z. Ziehl, Esq., and Debra Grassgreen, Esq., at Pachulski, Stang, Ziehl, Young, Jones & Weintraub LLP; Los Angeles, CA; (310) 277-6910

Notes: When the Debtors filed for bankruptcy, they estimated less than \$100,000 in assets and more than \$100 million in debts.

[Return to top](#)

**Prospector
Profile
07.0401**

Lexington Energy Services, Inc.
207 West Hastings Street, Suite 1209
Vancouver, British Columbia V6B 1H7
Canada
(604) 899-4550

| | | |
|---------------------------------|-------|----------|
| NAICS | | 333132 |
| Employees | | 31 |
| Revenue | (mil) | \$0.00 |
| Income | (mil) | (\$2.00) |
| Assets | (mil) | \$5.74 |
| Liability | (mil) | \$1.25 |
| (for the year ended 11/30/2006) | | |

Category: Audit Concerns

Event: Amisano Hanson expressed doubt that Lexington Energy Services, Inc. will be able to continue as a going concern after auditing its financial statements. The Company is dependent on its ability to raise capital from stockholders or other sources to sustain operations.

Intellectual Property: The Company own the intellectual property associated with its trade names and website at www.lexingtonenergyservices.com. [SEC Filing 10-KSB 03-12-07]

Description: The Company manufactures innovatively designed oilfield service equipment for a rapidly expanding industry.

Officers: Larry Kristof (Pres., CEO, CFO, Sec., Treas. & Dir.); Brent Nimeck (SVP, COO & Dir.)

Auditor: Amisano Hanson

Securities: Common Stock-Symbol LXES.OB; OTC BB;
22,289,178 common shares outstanding as of February 28, 2007.

[Return to top](#)

**Prospector
Profile
07.0402**

MathStar, Inc.

19075 Tanasbourne Drive, Suite 200
Hillsboro, OR 97124
(503) 726-5500

| | | |
|---------------------------------|-------|-----------|
| NAICS | | 334400 |
| Employees | | 63 |
| Revenue | (mil) | \$0.05 |
| Income | (mil) | (\$22.64) |
| Assets | (mil) | \$15.61 |
| Liability | (mil) | \$3.00 |
| (for the year ended 12/31/2006) | | |

Category: Loss/Deficit

Event: PricewaterhouseCoopers LLP raised doubts about MathStar, Inc.'s ability to continue as a going concern after auditing the Company's financial statements. The Company has a limited operating history and has incurred losses and negative cash flows from operations since inception. The Company expects to incur additional losses and will require additional funding to continue its operations.

Intellectual Property: The Company relies on a combination of United States patents, copyrights, trademarks, trade secret law, employee non-disclosure agreements and work-for-hire and non-disclosure agreements with independent contractors to protect and enforce intellectual property rights. The Company has been granted two United States patents, and has six patent applications on file with the United States Patent and Trademark Office. The Company currently holds common law trademark rights in MathStar, FPOA and ARRIX, and has pending federal trademark applications in the United States for the trademarks MathStar, FPOA and ARRIX. It also currently holds one domain name for MathStar.com, which is important to brand recognition and overall success. [SEC Filing 10-KSB 03-14-07]

Description: The Company engages in the design, development, manufacture, and marketing of semiconductor integrated circuit or chip, known as field programmable object arrays (FPOAs), in the United States.

Officers: Douglas M. Pihl (Chair, Pres. & CEO); James W. Cruckshank (VP & CFO); Benno G. Sand (Dir.); Merrill A. McPeak (Dir.); Morris Goodwin, Jr. (Dir.); Michael O. Maerz (Dir.)

Auditor: PricewaterhouseCoopers LLP

Securities: Common Stock-Symbol MATH; NasdaqGM;
20,931,890 common shares outstanding as of March 9, 2007.

[Return to top](#)

**Prospector
Profile
07.0403**

Megola, Inc.

446 Lyndock St., Suite 102
Corunna, Ontario N0N 1G0
Canada
(519) 481-0628

| | | |
|--------------------------------|-------|----------|
| NAICS | | 333319 |
| Employees | | 4 |
| Revenue | (mil) | \$0.74 |
| Income | (mil) | (\$0.86) |
| Assets | (mil) | \$0.37 |
| Liability | (mil) | \$0.53 |
| (for the year ended 7/31/2006) | | |

Category: Audit Concerns

Event: Malone & Bailey, PC raised doubts about Megola, Inc.'s ability to continue as a going concern due to its recurring losses from operations.

Intellectual Property: On July 4, 2006, the Company acquired from Uwe Pfefferle and Alois Sitter the Patent # US 6,485,624 B1 for the CDI (Capacitive Deionization) system, pending patent for a non-invasive pipe wrapping method for PWT (Physical Water Treatment) systems, and IP Rights for the ScaleGuard series (TFK, SG, SG100, SG200, SG300, SG400, SG500) of PWT systems. The patent is designed for the physical treatment of drinking water. No chemical treatment is needed to prepare drinking water adjusted to meet all environmental and health standards with respect to organic contaminations. [SEC Filing 10-KSB 03-12-07]

Description: The Company is a leading solutions provider in physical water treatment, wastewater treatment, microbiological control and air purification systems.

Officers: Joel Gardner (Pres., CEO & Dir.); Don Greer (COO & Dir.); Todd Clark (Sec. & Dir.)

Auditor: Malone & Bailey, PC

Securities: Common Stock-Symbol MGOA.PK; PNK;
37,716,029 common shares outstanding as of July 31, 2006.

[Return to top](#)

**Prospector
Profile
07.0404**

Monogram Biosciences, Inc.

345 Oyster Point Blvd.
South San Francisco, CA 94080
(650) 635-1100

| | | |
|---------------------------------|-------|-----------|
| NAICS | | 325413 |
| Employees | | 291 |
| Revenue | (mil) | \$48.25 |
| Income | (mil) | (\$37.59) |
| Assets | (mil) | \$60.85 |
| Liability | (mil) | \$46.94 |
| (for the year ended 12/31/2006) | | |

Category: Loss/Deficit

Event: Monogram Biosciences, Inc. reported a net loss of \$38.703 million on revenues of \$47.958 million for the year ended December 31, 2006, a slight increase compared to last year's net loss of \$37.586 million on revenues of \$48.252 million. As a result of its recurring losses, the Company has an accumulated deficit of \$263.991 million as of December 31, 2006. The Company also used cash from operating activities of \$24.178 million, higher than the \$13.746 million in 2005 and \$2.627 million in 2004.

Intellectual Property: With respect to its viral disease portfolio, the Company currently has approximately 98 granted, issued, allowed, and pending patent applications in the United States and in other countries, including 45 issued patents. With respect to potential oncology products and eTag technology, the Company currently has approximately 57 granted, issued, allowed, and pending patent applications in the United States and in other countries, including 20 issued patents. It also has 110 granted, issued, allowed, and pending patent applications in the United States and in other countries, including 87 issued or allowed patents, relating to the historic microfluidics business of ACLARA. The Company has also licensed certain patents and technologies. [SEC Filing 10-K 03-09-07]

Description: The Company engages in the development and commercialization of molecular diagnostic products focusing on infectious diseases, cancer and other diseases.

Officers: William D. Young (Chair & CEO); Alfred G. Merriweather (VP & CFO); Thomas R. Baruch (Dir.); Edmon Jennings (Dir.); William Jenkins (Dir.); Cristina H. Kepner (Dir.); David H. Persing (Dir.); John D. Mendlein (Dir.)

Auditor: PricewaterhouseCoopers LLP

Securities: Common Stock Symbol MGRM; NasdaqGM;
131,742,353 common shares outstanding as of March 5, 2007.

[Return to top](#)

**Prospector
Profile
07.0405****MTS, Inc.**

2500 Del Monte St.
West Sacramento, CA 95691
(916) 373-2502

NAICS

451220

Category: IP Asset Sale

Event: Caiman Holdings, Inc. has bought Tower Records trademark and Web site for \$4.2 million outbidding four other competitors, the Sacramento Business Journal reports. The sale includes the e-commerce business and a global trademark of Tower Records, which is registered in 37 countries. The Sacramento Bee further relates that with the purchase, Caiman Holdings could now operate the Web site and possibly open Tower Records stores in the United States and in some foreign countries.

Intellectual Property: The Company regards its trademarks and service marks as having significant worldwide value and as being important to its marketing efforts and brand name recognition. The Company has registered its TOWER RECORDS-VIDEO-BOOKS trademark and variations thereof, along with numerous other trademarks, with the United States Patent and Trademark Office. The Company also has registered its TOWER trademark, or variations thereof, in numerous foreign countries. The Company's policy is to pursue the registration of its trademarks whenever possible and to vigorously oppose any infringement of its trademarks and trade names. [SEC Filing 10-K 11-07-02]

Description: The Company is one of the largest specialty retailers of recorded music headquartered in the United States in terms of revenues and is one of the largest and most widely recognized music retailers in the world. The Company filed for Chapter 11 protection on February 9, 2004 with the Bankruptcy Court for the District of Delaware, case number 04-10394.

Officers: Kevin Cassidy (EVP); Russell Eisenman (VP); Shauna Pompei (Dir.)

Attorneys: Mark D. Collins, Esq. of Richards Layton & Finger; Wilmington, DE; (302) 651-7531

Notes: Estimated Assets: More than \$100 million
Estimated Debt: More than \$100 million

[Return to top](#)

**Prospector
Profile
07.0406**

Nanophase Technologies Corporation

1319 Marquette Drive
Romeoville, IL 60446
(630) 771-6708

| | | |
|---------------------------------|-------|----------|
| NAICS | | 541710 |
| Employees | | 60 |
| Revenue | (mil) | \$8.99 |
| Income | (mil) | (\$5.18) |
| Assets | (mil) | \$19.74 |
| Liability | (mil) | \$2.92 |
| (for the year ended 12/31/2006) | | |

Category: Loss/Deficit

Event: Nanophase Technologies Corporation reported a net loss for the year ended December 31, 2006 of \$5,177,830 on sales of \$8,990,838, slightly lower than last year's net loss \$5,383,611 on sales of \$6,801,907. As a result of its recurring losses, the Company has an accumulated deficit of \$62,745,471 at December 31, 2006. The Company also used cash for operating activities of \$3,186,096, higher than last year's \$4,408,535.

Intellectual Property: The Company relies primarily on a combination of patent, trademark, copyright, trade secret and other intellectual property law, non-disclosure agreements and other protective measures to protect its intellectual property. As of December 31, 2006, Nanophase owns or licenses 18 US patents and patent applications consisting of 10 issued or allowed US patents, 7 pending US patent applications, and 1 licensed US patent. The 10 owned US patents consist of 4 patents for its nanoparticle synthesis technologies, 2 for its surface treatment technologies and 4 for its nanoparticle applications. The Company's pending US patents consist of 3 in nanoparticle synthesis, 1 in nanoparticle surface treatments, and 3 in nanoparticle applications. Correspondingly, the Company owns 48 foreign patents and patent applications consisting of 23 issued or allowed foreign patents and 25 pending foreign patents applications. Nanophase has licensed its PVS technology for certain specific markets and certain geographies to C.I. Kasei, a division of Itochu Corporation. [SEC Filing 10-K 03-14-07]

Description: The Company engages in the development and manufacture of nanocrystalline materials in the United States.

Officers: Donald S. Perkins (Chair); Joseph E. Cross (Pres., CEO & Dir.); James A. Henderson (Dir.); James A. McClung, Ph.D. (Dir.); R. Janet Whitmore (Dir.); Richard W. Siegel, Ph.D. (Dir.); Jerry K. Pearlman (Dir.)

Auditor: McGladrey & Pullen, LLP

Securities: Common Stock-Symbol NANX; NasdaqGM; 19,001,509 common shares outstanding as of March 12, 2007.

[Return to top](#)

**Prospector
Profile
07.0407**

New Medium Enterprises, Inc.

195 The Vale
London, United Kingdom W3 7QS
+44 208-746-2018

| | | |
|--------------------------------|-------|----------|
| NAICS | | 334310 |
| Employees | | 8 |
| Revenue | (mil) | \$0.00 |
| Income | (mil) | (\$6.44) |
| Assets | (mil) | \$18.81 |
| Liability | (mil) | \$0.27 |
| (for the year ended 6/30/2006) | | |

Category: Audit Concerns

Event: Morgenstern Svoboda & Baer CPA's PC expressed doubt on New Medium Enterprises, Inc.'s ability to continue as a going concern. The auditor points out that the Company has no significant income, has incurred net losses since its inception and has experienced severe liquidity problems.

Intellectual Property: The Company has applied for three patents relating to VMD technologies and has applied for two provisional patents. The first comprehensive patent titled "Multi-layer quasi-reflective media and method of its manufacturing" has been filed initially as a provisional US patent application with the enlarged version prepared as regular PCT & US application which has been submitted in 2003. In addition, the Company acquired from TriGm International S.A. a portfolio of researched and isolated patentable inventions related to VMD technologies for which it plans to apply for patent protection in the future. The Company is strongly pursuing a commercial strategy for protecting the VMD technology. The Company also expects to develop new derivative concepts, as well as supplementary technological solutions and processes, resulting in patents and/or know-how, which will be expanded upon and enhance the original VMD concept and intellectual property. [SEC Filing 10-K/A 03-06-07]

Description: The Company provides the world's first low-cost true high definition medium solution utilizing red laser technology and existing DVD industrial infrastructure.

Officers: Mahesh Jaranayaran (CEO & Dir.); Dr. Eugene Levich (CTO & Dir.); Irene Kuan (CFO & Dir.); Alexander B. Hagerty (VP-Bus. Dev't.); Rupert Stow (Dir.); Barry Williamson (Dir.)

Auditor: Morgenstern Svoboda & Baer CPA's PC

Securities: Common Stock-Symbol NMEN.OB; OTC BB;
205,477,579 common shares outstanding as of June 30, 2006.

[Return to top](#)

**Prospector
Profile
07.0408**

OccuLogix, Inc.

2600 Skymark Avenue, Unit 9, Suite 201
Mississauga, Ontario L4W 5B2
Canada
(905) 602-0887

| | | |
|---------------------------------|-------|-----------|
| NAICS | | 423450 |
| Employees | | 37 |
| Revenue | (mil) | \$0.21 |
| Income | (mil) | (\$82.17) |
| Assets | (mil) | \$90.40 |
| Liability | (mil) | \$29.18 |
| (for the year ended 12/31/2006) | | |

Category: Audit Concerns

Event: Ernst & Young LLP expressed substantial doubt about OccuLogix, Inc.'s ability to continue as a going concern after auditing the Company's consolidated financial statements for the fiscal year ended December 31, 2006. The firm pointed to the Company's declining revenues, recurring losses from operations and reduction of its working capital from \$30,875,921 in 2005 to \$13,539,026 in 2006.

Intellectual Property: The Company's success depends in part on its ability to develop a competitive intellectual property advantage over potential competitors. One aspect of the RHEO™ System is a treatment method described in an issued U.S. patent which expires in 2017. This patent is directed to a process for treating ocular diseases using apheresis. It licenses this patent from the two co-owners of the patent under a separate license agreement with each owner. In addition, the Company owns one issued patent entitled "Rheological Treatment Methods and Related Apheresis Systems", which is directed to methods of screening and identifying patient candidates for RHEO™ Therapy. It also has three additional pending patent applications in the United States, Europe and Japan. In addition to patent protection, the Company has registered these U.S. trademarks: OCCULOGIX; RHEO CLINIC; VASCULAR SCIENCES; and RHEOPHERESIS. It also has the right to use these registered trademarks from Asahi Medical: Rheofilter and Plasmaflo. [SEC Filing 10-K 03-15-07]

Description: The Company offers treatments for eye diseases, including age-related macular degeneration.

Officers: Elias Vamvakas (Chair & CEO); William G. Dumencu (Interim CFO & Treas.); Jay T. Holmes (Dir.); Thomas N. Davidson (Dir.); Richard L. Lindstrom (Dir.); Georges Noël (Dir.); Adrienne L. Graves (Dir.); Gilbert S. Omenn (Dir.)

Auditor: Ernst & Young LLP

Securities: Common Stock Symbol OCCX; NasdaqGM;
57,303,895 common shares outstanding as of March 8, 2007.

[Return to top](#)

**Prospector
Profile
07.0409**

Panacos Pharmaceuticals, Inc.

134 Coolidge Avenue
Watertown, MA 02472
(617) 926-1551

| | | |
|---------------------------------|-------|-----------|
| NAICS | | 541710 |
| Employees | | 43 |
| Revenue | (mil) | \$0.28 |
| Income | (mil) | (\$38.11) |
| Assets | (mil) | \$65.65 |
| Liability | (mil) | \$6.97 |
| (for the year ended 12/31/2006) | | |

Category: Loss/Deficit

Event: Panacos Pharmaceuticals, Inc. reported a net loss of \$38.110 million for fiscal year ended December 31, 2006, compared to a net loss of \$59.078 million in 2005 and \$13.963 million in 2004. As a result of its recurring losses, the Company has an accumulated deficit of \$122.564 million as of December 31, 2006. The Company also used cash for operating activities of \$29.630 million in 2006, compared to \$21.646 million in 2005 and \$9.773 million in 2004.

Intellectual Property: The Company seeks to protect proprietary technology that is important to its business, including compounds, formulations and their methods of use. The Company also files patent applications in European countries and additional foreign countries, including Australia, Canada and Japan, on a selective basis. It relies upon trade secrets and contracts and confidentiality agreements to protect proprietary information. Currently, the Company's patent estate in antiviral therapeutics includes 9 issued U.S. patents and 17 pending U.S. applications. It also maintains a separate docket of 13 patent families claiming aspects of the INACTINE program. Each of the U.S. applications and patents has one or more corresponding foreign applications or patents. [SEC Filing 10-K 03-13-07]

Description: The Company engages in the discovery and development of small molecule oral drugs to treat human immunodeficiency virus (HIV) and other major human viral diseases.

Officers: Jeremy Hayward-Surry (Chair); Alan W. Dunton, M.D. (CEO & Dir.); Graham P. Allaway, Ph.D. (Pres. & COO); Peyton J. Marshall, Ph.D. (EVP & CFO); Alan W. Dunton, M.D. (Dir.); Laurent Fischer, M.D. (Dir.); John Fletcher (Dir.); Herbert H. Hooper, Ph.D. (Dir.); Irwin Lerner (Dir.); Joseph M. Limber (Dir.); Eric W. Linsley (Dir.)

Auditor: KPMG LLP

Securities: Common Stock-Symbol PANC; NasdaqGM;
52,877,594 common shares outstanding as of March 1, 2007.

[Return to top](#)

**Prospector
Profile
07.0410**

Physicians Remote Solutions, Inc.

64 Secretariat Court
Tinton Falls, NJ 48331
(732) 676-6030

NAICS 541219

| | | |
|-----------|-------|----------|
| Revenue | (mil) | \$0.00 |
| Income | (mil) | (\$0.12) |
| Assets | (mil) | \$0.04 |
| Liability | (mil) | \$0.02 |

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Meyler & Company, LLC expressed substantial doubt about Physicians Remote Solutions, Inc.'s ability to continue as a going concern. The Company has incurred cumulative net operating losses of \$125,489 since inception.

Intellectual Property: On June 10, 2004, Dr. Christina Del Pin filed a patent application for the DR SPEAK system with the United States Patent and Trademark Office. In March 2006, the United States Patent and Trademark Office notified Dr. Del Pin that the application will receive an Office action in 12 months. The claims made in the patent application do not encompass all aspects of the system. In April 2006, the United States Trademark Office issued a trademark registration for Dr. Del Pin's trademark "DR SPEAK." [SEC Filing 10-KSB 03-14-07]

Description: The Company has the exclusive rights to manufacture and sell a telephone-based voice activated billing and records entry system designed for use by physicians.

Officers: Christopher LaRose (Pres., CEO & Dir.); Lee Hanover (VP, Sec. & Dir.); Alfred Cella (Treas. & Dir.); Gary Cella (Dir.); Martin Horowitz (Dir.)

Auditor: Meyler & Company, LLC

Securities: 11,138,338 common shares outstanding as of March 12, 2007.

[Return to top](#)

**Prospector
Profile
07.0411**

Ply Gem Industries, Inc.

185 Platte Clay Way
Kearney, MO 64060
(816) 903-6400

| | | |
|---------------------------------|-------|------------|
| NAICS | | 326192 |
| Employees | | 4,600 |
| Revenue | (mil) | \$838.87 |
| Income | (mil) | \$20.23 |
| Assets | (mil) | \$1,050.00 |
| Liability | (mil) | \$834.48 |
| (for the year ended 12/31/2006) | | |

Category: Low Rating

Event: On March 12, 2007, Moody's Investors Service affirmed its Caa1, LGD5, 86% rating on Ply Gem Industries, Inc.'s \$360 million 9% senior subordinated notes due 2012. The rating outlook remains stable. Moody's said the rating may deteriorate if free cash flow after capital expenditures to total debt was to decline to under 3% on a projected annual basis or if the Company's debt to EBITDA increases above 6x.

Intellectual Property: The Company owns all of these trademarks and brands: Ambassador™, American, '76 Collection®, American Comfort®, American Herald®, American Splendor®, American Tradition®, Camden Pointe®, Cedar Select®, Chateau®, Consul™, Contractor's Choice®, Durabuilt®, Duragrain®, Diplomat™, Envoy™, Great Lakes®, Great Lakes Gold™, Hampton III®, Millbridge™, Monitor™, Napco®, Napco Premium 2000™, Napco Premium 3000™, Napco Prime™, Nostalgia Series®, Olde Providence®, Ply Gem™, Premier™, Regency™, Timber Oak®, Uniframe®, Varigrain Preferred® and Victoria Harbor®. [SEC Filing S-4 12-23-04]

Description: The Company manufactures and sells residential exterior building products like wood and vinyl windows and doors, vinyl siding, and wall and floor coverings. Its subsidiaries include Alenco Windows, CWD Windows and Doors, Great Lakes Window, Kroy Building Products, MW Windows, NAPCO, Inc., and Variform, Inc. The Company is part of Ply Gem Holdings, Inc., an investment vehicle associated with Caxton-Iseman Capital.

Officers: Frederick J. Iseman (Chair); Gary Robinette (Pres. & CEO); Shawn K. Poe (VP, CFO, Treas., & Sec.)

Auditor: KPMG LLP

Securities: 9% senior subordinated notes due 2012

Notes: Audited financial information provided is that of Ply Gem Holdings, Inc.

[Return to top](#)

**Prospector
Profile
07.0412**

Sand Technology, Inc.

215 Redfern, Suite 410
Westmount, Quebec H3Z 3L5
Canada
(514) 939-3477

| | | | |
|--------------------------------|----------|----------|--|
| NAICS | 511210 | | |
| Employees | 56 | | |
| Revenue | CAD(mil) | \$5.48 | |
| Income | CAD(mil) | (\$3.93) | |
| Assets | CAD(mil) | \$3.45 | |
| Liability | CAD(mil) | \$2.51 | |
| (for the year ended 7/31/2006) | | | |

Category: Loss/Deficit

Event: Sand Technology, Inc. reported a net loss of CAD3,926,921 on revenues of CAD5,477,485 for the fiscal year ended July 31, 2006, lower than last year's net loss of CAD7,363,054 on revenues of CAD6,096,033. As a result of its recurring losses, the Company has an accumulated deficit of CAD37,190,978 and stockholder's equity of only CAD936,778 at December 31, 2006.

Intellectual Property: The Company relies primarily on a combination of copyright and trademark laws, patents, trade secrets, confidentiality procedures and contractual provisions to protect proprietary rights. The Company seeks to protect software, documentation and other written materials under trade secret and copyright laws, which afford only limited protection. It currently has 8 United States patents and 32 foreign patents. It also relies on certain software licensed from third parties, including software that may be integrated with its internally-developed software and used in products to perform key functions. [SEC Filing 20-F 03-14-07]

Description: The Company is an international provider of intelligent information management software that helps enterprises economically store and easily retrieve large amounts of granular or historical data in order to meet changing business needs and regulations.

Officers: Arthur G. Ritchie (Chair & CEO); Gilles Therrien (VP & CFO); Martin Shindler (Dir.); George Wicker (Dir.); Douglas S. Pryde (Dir.)

Auditor: Raymond Chabot Grant Thornton LLP

Securities: Common Stock-Symbol SNDTF.OB; OTC BB; 12,818,189 common shares outstanding as of July 31, 2006.

[Return to top](#)

**Prospector
Profile
07.0413**

SCOLR Pharma, Inc.

3625 132nd Ave. S.E.
Bellevue, WA 98006
(425) 373-0171

| | | |
|---------------------------------|-------|-----------|
| NAICS | | 325413 |
| Employees | | 19 |
| Revenue | (mil) | \$2.28 |
| Income | (mil) | (\$10.74) |
| Assets | (mil) | \$18.49 |
| Liability | (mil) | \$2.37 |
| (for the year ended 12/31/2006) | | |

Category: Loss/Deficit

Event: SCOLR Pharma, Inc. reported a net loss of \$10,743,230 on revenues of \$2,278,449 for the year ended December 31, 2006, higher than last year's net loss of \$8,886,063 on revenues of \$635,407. As a result of its recurring losses, the Company has an accumulated deficit of \$47,053,678 at the end of fiscal year 2006. The Company also used cash for operating activities of \$8,972,962, compared to \$8,190,316 last year.

Intellectual Property: The Company believes that patent and trade secret protection of the CDT platform is important to its business. Its success will depend in part on the ability to maintain existing patent protection, obtain additional patents, maintain trade secret protection and operate without infringing the proprietary rights of others. The Company has rights to four U.S. patents and three federal trademark registrations. Its registered trademarks include: "CDT," the CDT logo and design, and "SCOLR." The Company's CDT platform is based on multiple issued and pending patents and other intellectual property for the programmed release or enhanced performance of active pharmaceutical ingredients and nutritional products. Its intellectual property includes two U.S. patents licensed exclusively by Temple University and two patent rights assigned by Dr. Reza Fassihi, a Professor of Biopharmaceutics and Industrial Pharmacy at the Temple University School of Pharmacy. [SEC Filing 10-K 03-13-07]

Description: The Company engages in the development and formulation of over-the-counter products, prescription drugs and dietary supplement products that use its patented controlled delivery technology (CDT).

Officers: Herbert L. Lucas (Chair); Daniel O. Wilds (Pres. & CEO); Alan M. Mitchel (SVP); Stephen J. Turner (VP & Chief Tech. Officer); Richard M. Levy (VP & CFO); Randall L-W. Caudill (Dir.); Reza Fassihi (Dir.); Herbert L. Lucas (Dir.); Michael Sorell (Dir.); Wayne L. Pines (Dir.); Hans Mueller (Dir.)

Auditor: Grant Thornton LLP

Securities: Common Stock-Symbol DDD; AMEX;
38,048,146 common shares outstanding as of March 1, 2007.

[Return to top](#)

**Prospector
Profile
07.0414**

Somaxon Pharmaceuticals, Inc.

3721 Valley Centre Drive, Suite 500
San Diego, CA 92130
(858) 480-0400

| | | |
|---------------------------------|-------|-----------|
| NAICS | | 541710 |
| Employees | | 37 |
| Revenue | (mil) | \$0.00 |
| Income | (mil) | (\$46.41) |
| Assets | (mil) | \$59.45 |
| Liability | (mil) | \$7.10 |
| (for the year ended 12/31/2006) | | |

Category: Loss/Deficit

Event: Somaxon Pharmaceuticals, Inc. reported a net loss of \$46.41 million for the fiscal year ended December 31, 2006, higher than the net loss of \$38.573 million in 2005 and \$13.598 million in 2004. As a result of its recurring losses, the Company has \$99.958 million in accumulated deficit at year end of 2006. The Company also used cash for operating activities of \$45.574 million, higher than the \$23.577 million used last year and \$10.942 million in 2004.

Intellectual Property: The Company is the exclusive licensee of four U.S. patents from ProCom One claiming the use of low dosages of doxepin and other antidepressants. The Company also licenses U.S. Patent No. 5,780,479 "Use of opioid antagonists to treat impulse-control disorders" from BioTie Therapies. It has exclusively in-licensed four U.S. issued patents from Synchronuron covering the use of acamprosate. The Company has received a Notice of Allowance from the U.S. Patent and Trademark Office for the trademark application for its corporate name, Somaxon Pharmaceuticals™. It has also applied for trademark registration for SILENOR™ in the U.S., Canada and Mexico, and has obtained a registration for this mark in Europe. [SEC Filing 10-K 03-14-07]

Description: The Company engages in the in-licensing, development, and commercialization of product candidates for the treatment of diseases and disorders in the fields of psychiatry and neurology in the United States.

Officers: David F. Hale (Chair); Kenneth M. Cohen (Pres., CEO & Dir.); Cam L. Garner (Dir.); Scott L. Glenn (Dir.); Jesse I. Treu, Ph.D. (Dir.); Daniel K. Turner III (Dir.); Kurt von Emster (Dir.); Kurt C. Wheeler (Dir.); Terrell A. Cobb (Dir.)

Auditor: PricewaterhouseCoopers LLP

Securities: Common Stock-Symbol SOMX; NasdaqGM;
18,111,717 common shares outstanding as of March 1, 2007.

[Return to top](#)

**Prospector
Profile
07.0415**

Stereotaxis, Inc.

4320 Forest Park Avenue, Suite 100
St Louis, MO 63108
(314) 678-6100

| | | |
|---------------------------------|-------|-----------|
| NAICS | | 339100 |
| Employees | | 180 |
| Revenue | (mil) | \$27.19 |
| Income | (mil) | (\$45.72) |
| Assets | (mil) | \$69.29 |
| Liability | (mil) | \$24.50 |
| (for the year ended 12/31/2006) | | |

Category: Loss/Deficit

Event: Stereotaxis, Inc. reported a net loss of \$45,719,770 for the year ended December 31, 2006 on revenues of \$27,191,706, compared to a net loss of \$43,557,835 on revenues of \$15,026,390 reported last year. As a result of its recurring losses, the Company has an accumulated deficit of \$203,950,839 as of December 31, 2006. The Company also used cash for operating activities of \$38,982,881, compared to \$40,986,183 last year.

Intellectual Property: The Company's strategy is to patent the technology, inventions and improvements that are important to the development of its business. As a result, the Company has an extensive patent portfolio that protects the fundamental scope of its technology, including magnet technology, navigational methods, procedures, systems, disposables interventional devices and 3D integration technology. As of December 31, 2006, the Company has 56 issued U.S. patents, 6 exclusively licensed U.S. patents, 1 exclusively licensed non-U.S. patent and 3 non-exclusively licensed U.S. patents. In addition, the Company had 113 pending U.S. patent applications, 7 co-owned U.S. patent applications, 9 licensed U.S. patent applications, 28 pending non-U.S. patent applications, and 20 Patent Cooperation Treaty applications. The Company also has a number of invention disclosures under consideration and several applications that are being prepared for filing. [SEC Filing 10-K 03-13-07]

Description: The Company engages in the design, manufacture, and marketing of cardiology instrument control system for the interventional treatment of coronary artery disease and arrhythmias in the United States and Europe.

Officers: Fred A. Middleton (Chair); Bevil J. Hogg (CEO); James M. Stolze (VP & CFO); Abhi Acharya (Dir.); Christopher Alafi (Dir.); David W. Benfer (Dir.); Gregory R. Johnson (Dir.); William M. Kelly (Dir.); Ralph G. Dacey, Jr. (Dir.); William C. Mills III (Dir.); Abhijeet J. Lele (Dir.); Robert J. Messey (Dir.); Eric N. Prystowsky (Dir.)

Auditor: Ernst & Young LLP

Securities: Common Stock-Symbol STXS; NasdaqGM;
34,835,427 common shares outstanding as of February 28, 2007.

[Return to top](#)

**Prospector
Profile
07.0416**

Sun-Times Media Group, Inc.

350 North Orleans Street, 10-S
Chicago, IL 60654
(312) 321-2299

| | | |
|---------------------------------|-------|------------|
| NAICS | | 511110 |
| Employees | | 2,841 |
| Revenue | (mil) | \$418.70 |
| Income | (mil) | (\$56.67) |
| Assets | (mil) | \$899.86 |
| Liability | (mil) | \$1,259.64 |
| (for the year ended 12/31/2006) | | |

Category: Loss/Deficit

Event: Sun-Times Media Group, Inc. posted a net loss of \$56,673,000 on revenues of \$418,700,000 for the fiscal year ended December 31, 2006, as compared with a net loss of \$11,566,000 on revenues of \$457,889,000 for the same year in 2005. As of December 31, 2006, the Company's balance sheet showed strained liquidity with \$392,923,000 in total current assets and \$757,113,000 in total current liabilities. The Company also had \$359,783,000 in stockholders' deficit and \$597,050,000 in accumulated deficit.

Intellectual Property: The Company seeks and maintains protection for its intellectual property in all relevant jurisdictions, and has current registrations, pending applications, renewals or reinstatements for all of its material trademarks. Internet domain names also form an important part of the Company's intellectual property portfolio. Currently, there are approximately 530 domain names registered in the name of the Company or its subsidiaries, including numerous variations on each major name. [SEC Filing 10-K 03-16-07]

Description: The Company, a subsidiary of Hollinger, Inc., publishes, prints, and distributes approximately 100 community newspapers and news products in the greater Chicago metropolitan area. It offers the Chicago Sun-Times, Post Tribune, Daily Southtown, Naperville Sun, other city and suburban newspapers, and associated Web sites.

Officers: Raymond G. H. Seitz (Chair); Cyrus F. Freidheim, Jr. (Pres. & CEO); John D. Cruickshank (COO); William G. Barker III (SVP-Finance); James McDonough (VP, Gen. Counsel, & Sec.); Thomas L. Kram (Chief Acctg. Officer & Controller); Dennis M. Byrd (Treas.); John F. Bard (Dir.); Herbert A. Denton (Dir.); John M. O'Brien (Dir.); Gordon A. Paris (Dir.); Graham W. Savage (Dir.); Raymond S. Troubh (Dir.)

Auditor: KPMG LLP

Securities: Common Stock Symbol SVN; NYSE;
80,227,397 common shares outstanding as of February 28, 2007.
9% senior notes due 2010

[Return to top](#)

**Prospector
Profile
07.0417**

Synthemed, Inc.

200 Middlesex Essex Turnpike, Suite 210
Iselin, NJ 08830
(732) 404-1117

| | | |
|-----------|-------|----------|
| NAICS | | 541710 |
| Employees | | 4 |
| Revenue | (mil) | \$0.14 |
| Income | (mil) | (\$3.90) |
| Assets | (mil) | \$4.18 |
| Liability | (mil) | \$0.85 |

(for the year ended 12/31/2006)

Category: Audit Concerns

Event: Eisner LLP raised substantial doubt about Synthemed, Inc.'s ability to continue as a going concern due to its recurring net losses, limited revenues and cash outflows from operating activities.

Intellectual Property: The Company currently holds 10 United States patents, 2 European patents, 1 Australian patent and 1 Canadian patent, relating to methods and compositions for reducing or eliminating post-surgical adhesion formation as well as bioresorbable polymeric compounds and polyurethane polymeric compounds. These patents are scheduled to expire on various dates from 2008 through 2023. The Company also holds 2 United States patents with claims for the treatment of trauma with a composition comprising a polyanionic polymer and for a composition comprising hydrolytically susceptible polyanionic polymer. It also has numerous patent applications pertaining to various novel bioresorbable polymeric compounds and, in certain instances, their use in post-operative adhesion prevention on file with the US and international patent agencies. [SEC Filing 10-KSB 03-09-07]

Description: The Company engages in the development and commercialization of anti-adhesion and drug delivery products.

Officers: Robert P. Hickey (Pres., CEO & CFO); Eli Pines, Ph.D. (VP & CSO)

Auditor: Eisner LLP

Securities: Common Stock-Symbol SYMD.OB; OTC BB;
83,021,479 common shares outstanding as of February 23, 2007.

[Return to top](#)

**Prospector
Profile
07.0418**

Take-Two Interactive Software, Inc.

622 Broadway
New York, NY 10012
(646) 536-2842

| | | |
|---------------------------------|-------|------------|
| NAICS | | 511210 |
| Employees | | 2,020 |
| Revenue | (mil) | \$1,037.84 |
| Income | (mil) | (\$184.89) |
| Assets | (mil) | \$868.81 |
| Liability | (mil) | \$318.41 |
| (for the year ended 10/31/2006) | | |

Category: Miscellaneous

Event: Take-Two Interactive Software, Inc. is evaluating alternative courses of actions, including a potential sale of the company, as a shareholder group seeks to control its board, Lisa Baertlein of Reuters reports. The Company has been battered by several years of accounting woes, operational problems, a scandal over hidden sexual content in its games, and a string of quarterly losses. It has also restated results due to both inflated revenue and improper use of employee stock options.

Intellectual Property: The Company develops proprietary software titles and has obtained the rights to publish and distribute software titles developed by third parties. The Company protects software and production techniques under copyright, trademark and trade secret laws as well as through contractual restrictions on disclosure, copying and distribution. The Company develops most of the software titles for its Rockstar label through internal development studios: Rockstar North, the developer of Grand Theft Auto and Manhunt; Rockstar San Diego, the developer of Midnight Club, Rockstar Games Presents Table Tennis, Smuggler's Run and Red Dead Revolver; Rockstar Toronto, the developer of The Warriors for PlayStation 2 and Xbox, as well as the PlayStation 2 version of Max Payne; Rockstar Vancouver, the developer of Bully; and Rockstar Leeds, the developer of the PSP versions of Grand Theft Auto: Liberty City Stories, Grand Theft Auto: Vice City Stories; Midnight Club 3: DUB Edition, and The Warriors. While many of its 2K Games titles are developed by third-party developers, the Company also develops software titles for 2K Games label through internal development studios. [SEC Filing 10-K 02-28-07]

Description: The Company engages in the development, publication, and distribution of interactive software games.

Officers: Paul Eibeler (Pres., CEO & Dir.); Karl H. Winters (CFO); Samuel A. Judd (SVP); Grover C. Brown, Esq. (Dir.); Todd Emmel (Dir.); Robert Flug (Dir.); Oliver R. Grace, Jr. (Dir.); John F. Levy (Dir.); Mark Lewis (Dir.); Michael J. Malone (Dir.); Steven Tisch (Dir.)

Auditor: Ernst & Young LLP

Securities: Common Stock-Symbol TTWO; NasdaqGM;
72,838,149 common shares outstanding as of February 16, 2007.

[Return to top](#)

**Prospector
Profile
07.0419**

TowerStream Corporation

55 Hammarlund Way
Middletown, RI 02842
(401) 848-5848

| | | |
|---------------------------------|-------|----------|
| NAICS | | 517212 |
| Revenue | (mil) | \$0.00 |
| Income | (mil) | (\$0.07) |
| Assets | (mil) | \$0.02 |
| Liability | (mil) | \$0.02 |
| (for the year ended 12/31/2006) | | |

Category: Audit Concerns

Event: Schumacher & Associates, Inc. raised doubts about TowerStream Corporation's ability to continue as a going concern because the Company has had minimal operations to date and has incurred losses since inception.

Intellectual Property: The Company's University Girls Calendar, Ltd. subsidiary developed a branding strategy for its products, including stylized names, logos and layout templates. These trademarks appeared throughout its calendar products and website, and on the t-shirts, hats and other clothing offered for sale. The Company believes that these trademarks helped consumers identify and differentiate its product. In terms of identifying words, the Company used "University Girls Calendar", "Halifax University Girls" and "Nova Scotia University Girls", in association with its products. The Company did not register its trademarks with the United States and Canada trademark offices, and trademark protection is limited to available common law protection. [SEC Filing 10-KSB 03-13-07]

Description: The Company provides wireless broadband network services to subscribers in New York City, Chicago, Los Angeles, Boston and Providence, Rhode Island.

Officers: Philip Urso (Chair); Jeffrey M. Thompson (Pres., CEO & Dir.); George E. Kilguss, III (CFO); Arthur G. Giftakis (VP-Eng'g.); Howard L. Haronian, M.D. (Dir.); Paul Koehler (Dir.); William Bush (Dir.)

Auditor: Schumacher & Associates, Inc.

Securities: 23,724,950 common shares outstanding as of February 28, 2007.

[Return to top](#)

**Prospector
Profile
07.0420**

Tripes, Incorporated

1699 S. Hanley Rd.
St. Louis, MO 63144
(314) 647-1099

| | | |
|---------------------------------|-------|----------|
| NAICS | | 511210 |
| Employees | | 327 |
| Revenue | (mil) | \$55.42 |
| Income | (mil) | (\$4.29) |
| Assets | (mil) | \$66.82 |
| Liability | (mil) | \$37.30 |
| (for the year ended 12/31/2005) | | |

Category: Miscellaneous

Event: Tripes, Inc., disclosed that its proposals to sell the assets of its Discovery Informatics business to Vector Capital and to adopt a plan of dissolution and liquidation of the company following completion of that sale were each approved by the required stockholder vote on March 16, 2007. Closing of the Vector Capital sale is expected to occur early this week. Liquidation of the company will occur following resolution of all corporate debts and obligations, and will commence approximately six months from now.

Intellectual Property: The Company licensed its workstation software through the execution of license agreements with each customer. The Company relies upon a combination of patent, copyright, trademark, and trade secret laws to protect its intellectual property. License and non-disclosure agreements are used to establish and protect the proprietary rights in its products. The Company holds four key patents in the area of analysis of the relationship of chemical structure to activity: one issued in the early 1990's on its SYBYL CoMFA product, another issued in 1998 on its Hologram QSAR, and two on its ChemSpace technology issued in 2001. In addition, the Company has patents on its compound selection, library design, and visualization technologies and on pKA prediction methodology. The source code for its products is protected both as trade secret and as unpublished, copyrighted work. In addition, its core software products are developed and manufactured only at its facilities. The Company does not disclose the source code for its products to any of its distributors. [SEC Filing 10-K 04-12-06]

Description: The Company offers informatics and research products and services for drug discovery.

Officers: Ralph S. Lobdell (Chair); John P. McAlister, III (Pres., CEO & Dir.); B. James Rubin (SVP & Sec.); John D. Yingling (VP, Chief Acctg. Officer & CFO); Stewart Carrell (Dir.); Gary Meredith (Dir.); Ferid Murad (Dir.); Alfred Alberts (Dir.)

Auditor: BDO Seidman LLP

Securities: Common Stock-Symbol TRPS; NasdaqGM;
10,281,712 common shares outstanding as of November 13, 2006.

[Return to top](#)

**Prospector
Profile
07.0421**

Unigene Laboratories, Inc.

110 Little Falls Road
Fairfield, NJ 07004
(973) 882-0860

| | | |
|---------------------------------|-------|-----------|
| NAICS | | 541710 |
| Employees | | 91 |
| Revenue | (mil) | \$6.06 |
| Income | (mil) | (\$11.78) |
| Assets | (mil) | \$14.05 |
| Liability | (mil) | \$28.24 |
| (for the year ended 12/31/2006) | | |

Category: Audit Concerns

Event: Grant Thornton LLP expressed substantial doubt about Unigene Laboratories, Inc.'s ability to continue as a going concern after auditing the Company's financial statements for the fiscal year ended December 31, 2006. The auditing firm pointed to the Company's recurring losses from operations, working capital deficiency, and stockholder demand loans in default at December 31, 2006.

Intellectual Property: The Company has filed a number of applications for U.S. patents relating to proprietary peptide manufacturing process and delivery technologies. To date, nine U.S. patents have been issued, including five patents covering improvements in manufacturing technology; three patents covering oral delivery of peptides; and one patent covering nasal calcitonin formulation. The manufacturing patents gives the Company a competitive advantage in producing peptides cost-effectively and in large quantities, because they cover a highly efficient bacterial fermentation process for producing peptides. The oral delivery patents gives the Company a competitive advantage to develop peptide products in oral forms, because they cover a process allowing delivery of significant quantities of peptides into the bloodstream. The nasal formulation patent gives the Company a competitive advantage to deliver the desired amount of calcitonin without requiring the presence of compounds that have been shown to cause irritation to the lining of the nasal cavity. [SEC Filing 10-K 03-16-07]

Description: The Company researches, produces, and delivers peptide-related products for medical use such as the treatment of osteoporosis, including nasal and oral calcitonin.

Officers: Warren P. Levy (Pres., CEO, & Dir.); Ronald S. Levy (EVP, Sec., & Dir.); Jay Levy (Treas. & Dir.); J. Thomas August (Dir.); Allen Bloom (Dir.); Robert F. Hendrickson (Dir.); Marvin L. Miller (Dir.); Bruce S. Morra (Dir.); Peter Slusser (Dir.)

Auditor: Grant Thornton LLP

Securities: Common Stock Symbol UGNE.OB; OTCBB;
87,731,015 common shares outstanding as of March 6, 2007.

[Return to top](#)

**Prospector
Profile
07.0422**

WorldGate Communications, Inc.

3190 Tremont Avenue
Trevose, PA 19053
(215) 354-5100

| | | |
|---------------------------------|-------|-----------|
| NAICS | | 334210 |
| Employees | | 70 |
| Revenue | (mil) | \$2.78 |
| Income | (mil) | (\$17.61) |
| Assets | (mil) | \$14.57 |
| Liability | (mil) | \$12.56 |
| (for the year ended 12/31/2006) | | |

Category: Audit Concerns

Event: Marcum & Kliegman LLP expressed substantial doubt about WorldGate Communications Inc.'s ability to continue as a going concern after auditing the Company's consolidated financial statements for the fiscal year ended December 31, 2006. The auditing firm pointed to the Company's recurring losses from operations and accumulated deficit.

Intellectual Property: The Company relies on patent, trade secret, trademark and copyright law to protect its video phone intellectual property. Although it has filed multiple patent applications for products and technology, the Company currently only holds one issued patent in the United States for a design patent issued in December 2006 and valid for a 14-year term. [SEC Filing 10-K 03-16-07]

Description: The Company designs, manufactures, and distributes personal video phones.

Officers: Hal M. Krisbergh (Chair & CEO); Rich Westerfer (SVP & COO); Joel I. Boyarski (SVP & CFO); Randall J. Gort (SVP, Chief Legal Officer, & Secretary); James McLoughlin (SVP); Clarence L. Irving, Jr. (Dir.); Jeff Morris (Dir.); Lemuel A. Tarshis (Dir.); Steven C. Davidson (Dir.); Martin Jaffe (Dir.)

Auditor: Marcum & Kliegman LLP

Securities: Common Stock Symbol WGAT; NasdaqCM;
42,260,446 common shares outstanding as of March 9, 2007.

[Return to top](#)